Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 multiple ascending dose study in healthy volunteers with extension in renal impairment
NL-OMON33878Phase 1Active, not recruiting
- Sponsor
- Araim Pharmaceuticals, Inc
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic kidney disease (CKD) and allergy comparing ARA 290 with Placebo (2 arms). Primary endpoints: Safety and tolerability after multiple dosing, Pharmacokinetics after multiple dosing and 2 more. Started Sep 2008; status: active, not recruiting.
02
Drugs
cibinetide
03
Conditions
chronic kidney disease (CKD)allergy
Beyond the preview
Go deeper on NL-OMON33878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33878.